Biodel Inc. (Nasdaq: BIOD) reported positive preliminary results from a Phase 2 clinical trial of its ultra rapid acting mealtime insulin to treat patients with type 1 diabetes but the stock price plunged $1.14 to $3.90.
Biodel Plunges
September 09, 2013 at 12:58 PM EDT
